5VM
5AM Venture Management Portfolio holdings
AUM
$260M
This Quarter Return
-11.1%
1 Year Return
+3.76%
3 Year Return
+144.87%
5 Year Return
+32.61%
10 Year Return
–
AUM
$447M
AUM Growth
+$447M
(+0.1%)
Cap. Flow
+$27.2M
Cap. Flow
% of AUM
6.07%
Top 10 Holdings %
Top 10 Hldgs %
73.55%
Holding
30
New
4
Increased
1
Reduced
3
Closed
2
Top Buys
| 1 |
Skye Bioscience
SKYE
|
$81.5M |
| 2 |
Erasca
ERAS
|
$12.8M |
| 3 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$10.6M |
| 4 |
Biohaven
BHVN
|
$5.21M |
| 5 |
EyePoint Pharmaceuticals
EYPT
|
$435K |
Top Sells
| 1 |
Enliven Therapeutics
ELVN
|
$28.6M |
| 2 |
Merus
MRUS
|
$24.7M |
| 3 |
Avidity Biosciences
RNA
|
$17M |
| 4 |
Cidara Therapeutics
CDTX
|
$12.9M |
| 5 |
Dianthus Therapeutics
DNTH
|
$235K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Zentalis Pharmaceuticals
ZNTL
$122M
| $2M | 0.45% |
490,000
| – | – |
|
|
27
Cidara Therapeutics
CDTX
$1.66B
| $677K | 0.15% |
56,725
-1,077,786
| -95% | -$12.9M |
|
|
28
EyePoint Pharmaceuticals
EYPT
$797M
| $435K | 0.1% |
+50,000
| New | +$435K |
|
|
29
Merus
MRUS
$4.98B
| – | – |
-548,825
| Closed | -$24.7M |
|
|
30
Avidity Biosciences
RNA
$5.99B
| – | – |
-665,555
| Closed | -$17M |
|